AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02664740
Drug: Topical anti-Staphylococcus bacteriophage therapy
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to the experimental arm will receive sterile compress dressings impregnated with a phage solution of 10\^7 PFU/ml on days 0, 7 and 14 (unless the wound is already healed, i.e. phage solutions are not applied to healed wounds).
Trial: NCT02664740
Drug: Topical placebo corresponding to anti-Staphylococcus bacteriophage therapy
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to the placebo arm will receive sterile compress dressings impregnated with a placebo solution on days 0, 7 and 14 (unless the wound is already healed, i.e. placebo solutions are not applied to healed wounds).
Trial: NCT06277609
Drug: Acetylsalicylic Acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT06277609
Drug: Mefenamic Acid
RxNorm normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT05972122
Drug: Analgesia management; group S and C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient-controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol including 10 mcg bolus without infusion dose, 10 min lockout time, and 4-hour limit. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
Trial: NCT04812236
Drug: Wulingsan co-decoction granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wulingsan co-decoction granules, the prescription is Alisma, Polyporus, Atractylodes, Poria, Guizhi. Oral, 2 times a day, 2 sachets each time, rinsed with warm water
Trial: NCT04812236
Drug: Wulingsan granule simulant
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wulingsan granule simulant, the prescription is Alisma, Polyporus, Atractylodes, Poria, Guizhi. Oral, 2 times a day, 2 sachets each time, rinsed with warm water
Trial: NCT04826172
Drug: IMB-1018972
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified release (MR) oral tablet
Trial: NCT04826172
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching oral tablet
Trial: NCT05229562
Drug: BIIB122
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT05071794
Drug: saline 0.9%
RxNorm normalized name: CVS Saline 0.9% Nasal Mist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05626959
Drug: NTI164
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oil based. Full-spectrum medicinal cannabis plant extract with less than 0.08% THC.
Trial: NCT05591755
Drug: Experimental: Vehicle ophthalmic solution (n = 56)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental: Vehicle ophthalmic solution (n = 56)
Trial: NCT06223048
Drug: AMDX-2011P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMDX-2011P single bolus injection intravenous for diagnostic review
Trial: NCT06331494
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butylphthalide Placebo injection for 10±3 days, oral Butylphthalide Placebo soft capsules for day 11±3 to day 180.
Trial: NCT06394375
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given as analgesia in opioid balanced anesthesia (control) group
Trial: NCT05234853
Drug: PUR001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibody
Trial: NCT05232461
Drug: Celecoxib 200mg
RxNorm normalized name: CELECOXIB 200MG CAP
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib
Trial: NCT06248229
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing will begin the morning following Visit 2. Subjects in the placebo group will begin the study on 5 mg of placebo. Subjects will be advised to take one tablet each morning upon awakening, dosed consistently with respect to time. Subjects will be advised that tablets should be swallowed whole, not crushed, chewed, or cut. Subjects can take Dyanavel XR with or without food.~Subjects will return to the study site on a weekly (and later, bi-weekly) basis for evaluation of symptoms and possible side effects. Subjects will be titrated to their optimal dose based on the dose titration schedule displayed in Section 5.1. The PI will be available to consult with patients as needed between Week 0 and Week 4 to adjust dosage per the PI's clinical judgment.
Trial: NCT06217939
Drug: Early hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: For the Early Hydrocortisone group, 50 mg of hydrocortisone in 10 ml of normal saline will be given as an intravenous bolus, then 200 mg of hydrocortisone in 100 ml of normal saline will be given as continuous intravenous infusion in 24 hours for 2 consecutive days (total 250 mg in day 1 and 200 mg in day 2).~After completion of the study drugs for 2 days, the study drug will be discontinued without tapering.
Trial: NCT06217939
Drug: Open-label hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: An open-label 50 mg of hydrocortisone given as an intravenous bolus followed by intravenous hydrocortisone 200 mg/day given as continuous infusion or divided bolus administration is suggested to be commenced in both study arms if the hemodynamic goal of the patient is not reached despite the dose of norepinephrine or epinephrine ≥ 0.25 mcg/kg/min at least 4 hours after the initiation of the vasopressors as recommended by the guideline. The study drug in each arm will be discontinued once an open-label hydrocortisone is initiated. Capillary or venous blood glucose will be tested at least every 6 hours for 2 days then at least once daily or more as appropriate for the first 7 days as a part of the study protocol.
Trial: NCT06106685
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The control group will be given equal volume placebo (120ml carrier solution matching the volume of WMT-001), which contains 10% sterile glycerol and saline injection. The drug was administered once a day for 4 days.
Trial: NCT05990452
Drug: 9MW2921
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will receive 9MW2921 by intravenous (IV) every 3 weeks.
Trial: NCT04938752
Drug: DA-2811-R
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose administration (one tablet once a day)
Trial: NCT05864391
Drug: AZD7503
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each participant is expected to be in the study for approximately 24 weeks, including a screening period of up to 28 days, a 12-week study intervention period, and a follow-up visit at week 18 (10 weeks following the final dose). Participants will be randomly assigned in a 3:1 ratio to receive AZD7503 or placebo. Study intervention will be administered via subcutaneous injection.
Trial: NCT04502394
Drug: KRT-232
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth
Trial: NCT05330429
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously
Trial: NCT05330429
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously
Trial: NCT05354817
Drug: mFOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFIRINOX: - Oxaliplatin; Leucovorin; Irinotecan and 5-FU
Trial: NCT05517616
Drug: [14C ]APG-2575
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally, single dose of 400 mg / 200 μCi \[14C\] APG-2575
Trial: NCT05512182
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab : 200mg/Q3W/IV infusion/Day 1of each 3-week cycle Neratinib : Week 1: 120 mg, Week 2: 160 mg, Week 3 and onwards: 240 mg/QD/Oral/Once daily Paclitaxel : 175mg/m2 /Q3W/IV infusion/Day 1of each 3-week cycle
Trial: NCT05507515
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets matching ONO-2020 tablets
Trial: NCT05985590
Drug: Drospirenone/Ethinyl Estradiol
RxNorm normalized name: DROSPIRENONE/ETHINYL ESTRADIOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT04530149
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: receive ketamine 0.15 mg/kg IV in 100 mL normal saline over 30 minutes for pain
Trial: NCT06246162
Drug: Lipo-MIT combination regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial diagnosis induction treatment regimen Lipo-MIT +VD (VMD):~Mitoxantrone Hydrochloride Liposome: 10 mg, d1, d15, intravenous infusion; Bortezomib: 1.3mg/m2 d1, 4, 8, 11, subcutaneous injection; Dexamethasone: 20 mg/d, orally on days 1, 2, 4, 5, 8, 9, 11, and 12. Every 4 weeks constitutes a cycle, and 4 cycles of VMD regimen induction therapy are performed.~Reinduction therapy regimen after relapse Lipo-MIT + PD (PMD):~Mitoxantrone Hydrochloride Liposome: 10 mg, d1, d15, intravenous infusion; Pomalidomide: 4 mg/d d1-d21, orally; Dexamethasone: 20 mg/d, orally on days 1, 2, 4, 5, 8, 9, 11, and 12. Every 4 weeks constitutes a cycle, and 4 cycles of PMD regimen induction therapy are performed.
Trial: NCT05193292
Drug: XELOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin, 130 mg/m2, iv, d1; Capecitabine, 1000 mg/m2, po, bid, d1-d14; q3w
Trial: NCT05193292
Drug: mFOLFOX6 regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin, 85 mg/m2, iv, d1; Leucovorin, 400 mg/m2, iv, d1; 5-FU, 400mg/m2, iv, d1 followed by 1200 mg/(m2·d)\*2d, civ, 46h; q2w
Trial: NCT05193292
Drug: FOLFIRI regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan, 180 mg/m2, iv, d1; Leucovorin, 400 mg/m2, iv, d1; 5-FU, 400mg/m2, iv, d1 followed by 1200 mg/(m2·d)\*2d, civ, 46h; q2w
Trial: NCT05193292
Drug: mXELIRI regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan, 200 mg/m2, iv, d1; capecitabine, 800 mg/m2, po, bid, d1-d14; q3w
Trial: NCT05193292
Drug: mIRIS regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan, 180 mg/m2, iv, d1; Tiggio Capsules (S-1), 40-60 mg/m2, po, bid, d1-d9; q2w
Trial: NCT04771780
Drug: KHK7791
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT05280223
Drug: Hyalase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injection of Hyalase + 10 cc saline injection nearby median nerve as hydro-dissection
Trial: NCT06427863
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive three consecutive enemas of placebo of equal volume through the TET tube, followed by WMT treatment once daily for a duration of 3 days
Trial: NCT04709406
Drug: deep neuromuscular blockade in bariatric surgery
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: obese patients who underwent bariatric surgery
Trial: NCT06181695
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of intranasal sufentanil
Trial: NCT05412160
Drug: Arginine
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: During the first assessment the patients will be randomized to receive BioArginine C™ twice daily on top of chronic inhaled therapy or to continue their chronic Inhaled therapy plus placebo for 6 weeks. The main purpose is to compare changes in CRQ from baseline and after 6 weeks in the interventional arm compared with the control group in order to evaluate whether in symptomatic patients with COPD, daily bioarginine on top of chronic inhaled therapy can improve respiratory symptoms and dyspnea. The secondary objective of the study is to determine whether there is any correlation between improvement in respiratory symptoms and distance walked at the 6MWT and lung function parameters.
Trial: NCT06704555
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/m2 IV day 3
Trial: NCT06704555
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m2 IV day 3
Trial: NCT06706388
Drug: nL-ATN1-002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized antisense oligonucleotide
Trial: NCT05412160
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the first assessment the patients will be randomized to receive BioArginine C™ twice daily on top of chronic inhaled therapy or to continue their chronic Inhaled therapy plus placebo for 6 weeks. The main purpose is to compare changes in CRQ from baseline and after 6 weeks in the interventional arm compared with the control group in order to evaluate whether in symptomatic patients with COPD, daily bioarginine on top of chronic inhaled therapy can improve respiratory symptoms and dyspnea. The secondary objective of the study is to determine whether there is any correlation between improvement in respiratory symptoms and distance walked at the 6MWT and lung function parameters.
Trial: NCT05648006
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m2, orally administered twice a day, D1 to D14, repeated every 3 weeks
Trial: NCT06228365
Drug: Neuroleptanalgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual neuroleptanalgesic treatment
Trial: NCT05373186
Drug: Euglycemic clamp with BC Combo THDB0207
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of a single dose of BC Combo THDB0207 during an euglycemic clamp procedure
Trial: NCT05373186
Drug: Euglycemic clamp with Humalog® Mix25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of a single dose of Humalog® Mix25 during an euglycemic clamp procedure
Trial: NCT05373186
Drug: Euglycemic clamp with Humalog® and Lantus®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous administration of Humalog® and Lantus® during an euglycemic clamp procedure
Trial: NCT05068726
Drug: 18F Fluoroestradiol Radiopharmaceutical with PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of one dose of 18F FES for PET/CT imaging
Trial: NCT05705687
Drug: BEP Protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anticancer therapy
Trial: NCT05705687
Drug: Dose-dense regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-BEP-Oxaliplatin followed by Cisplatin - Ifosfamide - Paclitaxel
Trial: NCT05891366
Drug: WAL0921
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational product WAL0921
Trial: NCT05891366
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo product
Trial: NCT05368831
Drug: NST-1024
RxNorm normalized name: GLOVE NITRILE SM PFREE NSTERL TX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug Drug interactions between NST-1024 and caffeine (and paraxanthine), flurbiprofen, omeprazole, metoprolol, and midazolam
Trial: NCT06425224
Drug: Standard treatment (dapoxetine 30 mg as needed)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this group will receive dapoxetine 30 mg, taken 3 to 4 hours before sexual intercourse, for the 12 weeks of the study
Trial: NCT05061758
Drug: LY3056480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3056480 is an inhibitor of gamma-secretase
Trial: NCT06208410
Drug: Capecitabine Tablets
RxNorm normalized name: Capecitabine Tablets
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine Tablets is administered once daily, orally
Trial: NCT04615949
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 2.5 mg/kg to 7.5 mg/kg of body weight b.i.d taken orally with food
Trial: NCT04905563
Drug: Acetaminophen-Hydrocodone
RxNorm normalized name: acetaminophen-hydrocodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narcotic
Trial: NCT06104449
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablets to be taken orally as a recue medication.
Trial: NCT05363449
Drug: UHE-103 Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UHE-103 is an investigational combinational therapy containing keratolytic and antifungal
Trial: NCT05794672
Drug: Elarekibep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive single or multiple inhaled doses A, B or C, or single IV dose D of elarekibep.
Trial: NCT05794672
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive single or multiple inhaled doses A, B or C.
Trial: NCT05681650
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously at a total dose of 15-30mg/kg on day -3 and day-2
Trial: NCT04669028
Drug: NE3107
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NE3107 is an investigational orally bioavailable, blood-brain barrier permeable anti-inflammatory agent with a new mechanism of action targeting multiple mechanisms of pathology in Alzheimer's disease.
Trial: NCT04669028
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules that do not contain NE3107
Trial: NCT05387083
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy Volunteers will receive a single dose of placebo on Day 1.
Trial: NCT05177939
Drug: NPB-01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPB-01 will be administered for the treatment of autoimmune encephalitis
Trial: NCT06147544
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously once a week
Trial: NCT05941793
Drug: MBS-COV
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MBS-COV for inhalation
Trial: NCT05941793
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for inhalation
Trial: NCT06511973
Drug: Naproxen (BAYH006689)
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BAYH006689 gel will be dispensed directly on the patch
Trial: NCT06511973
Drug: Placebo Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel will be dispensed directly on the patch
Trial: NCT06511973
Drug: A solution of 0.9% Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% Saline will be dispensed directly on the patch
Trial: NCT06511973
Drug: A solution of 0.2% SLS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% SLS will be dispensed directly on the patch.
Trial: NCT05612191
Drug: AL3818
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It inhibits VEGFR2-mediated downstream signal transduction, thereby inhibiting tumor angiogenesis. It also has high potency against FGFr as well as VEGFr, and as such acts as a mainly dual inhibitor.
Trial: NCT05671692
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same as active comparator, except placebo dispensed.
Trial: NCT04986202
Drug: AZD4831
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD4831
Trial: NCT05180851
Drug: Recombinant L-IFN adenovirus injection
RxNorm normalized name: COVID-19 VACCINE ADENOVIRUS-26
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Before use, dilute the product with normal saline according to the size of the tumor to an appropriate volume (10-30% of the total volume of the tumor), or adjust appropriately according to the specific tumor situation, inject directly into the tumor or inject under the guidance of B ultrasound /CT, inject the drug solution into the tumor edge and tumor evenly
Trial: NCT05104853
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNP-104 Placebo
Trial: NCT04922814
Drug: muscle relaxation
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: They will receive muscle relaxation treatment for at least 48 hours. Cisatracurium will be given. Short term infusions up to 24 hours will be given in a dose rate of 2-3 mic/Kg/min followed by intervallic shots of 2-5 mg.
Trial: NCT00396968
Drug: AMD3100
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05302999
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inert cellulose
Trial: NCT04033029
Drug: Antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic concentration-time data will be collected and analyzed.
Trial: NCT00002403
Drug: Zintevir
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05007587
Drug: mFOLFOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAIC was performed every 3 weeks. The mFOLFOX regimen was administered via hepatic artery: oxaliplatin , 85mg/m2 , from hour 0 to 2 on day1 ; leucovorin , 400mg/m2 , from hour 2 to 3 on day 1 ; fluorouracil , 400mg/m2 , bolus at hour 3 ; and 2400mg/m2 over 46 hours on days 1 and 2.3mg/m2 , from hour 4 to 5 on day 1.